Spondyloarthritis & psoriatic arthritis
Comorbidities in the Spondyloarthritis GISEA Cohort: an average treatment effect analysis on patients treated with bDMARDs
Authors' conclusion
Overall, our study confirms the safety of TNFi and anti-IL in SpA patients, albeit with some caveats pertaining to solid cancers, OGID and fibromyalgia.
Study context
- Population
- Spondyloarthritis (SpA) patients from the multicentre Italian GISEA Registry
- Participants
- 4,458 patients
- Exposure
- Tumour necrosis factor inhibitors (TNFi) and anti-IL vs no treatment
- Outcome
- Main findings: solid cancer, other gastrointestinal diseases (OGID) and fibromyalgia (ATE analysis of comorbidity risk by treatment exposure)
Methodological detailsmulticentre, average treatment effect analysis
- Multicentre
- Average treatment effect analysis
Main finding
As reported in the abstract
Solid cancer (ATE)
Average treatment effect (ATE)
0.42
95% CI 0.20–0.85
G1
ATE
0.26
95% CI 0.08–0.71
G2
G0
14.07
incidence · /1000 patient-years
- Significantly higher incidence of solid cancer in G0
- P = 0.0001
Observational data: associations, not effects.
Further findings
| Outcome | ATE (95% CI) |
|---|---|
| Other gastrointestinal diseases (OGID) (ATE)G1 vs G0 | 1.56 (1.06–2.33) |
| Other gastrointestinal diseases (OGID) (ATE)G2 vs G0 | 1.91 (1.05–3.24) |
| FM (ATE)G1 vs G0 | 1.69 (1.05–2.68) |
| FM (ATE)G2 vs G0 | 2.13 (1.14–3.41) |
Haematological malignancies, cardiovascular events and endocrinological comorbidities
- No treatment risk reduction observed
Original publication
Comorbidities in the Spondyloarthritis GISEA Cohort: an average treatment effect analysis on patients treated with bDMARDs. Clin Exp Rheumatol. Published 8 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →